SAM
PTGX icon

Smartleaf Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Smartleaf Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.9K Sell
890
-837
-48% -$74.1K ﹤0.01% 1180
2025
Q4 		$151K Buy
1,727
+324
+23% +$26.5K 0.01% 958
2025
Q3 		$91.4K Buy
1,403
+146
+12% +$8.3K 0.01% 1121
2025
Q2 		$70K Buy
1,257
+46
+4% +$2.21K 0.01% 1014
2025
Q1 		$59.2K Buy
1,211
+710
+142% +$29.8K 0.01% 1062
2024
Q4 		$19.3K Buy
501
+411
+457% +$17.9K ﹤0.01% 1659
2024
Q3 		$4.01K Buy
90
+75
+500% +$3.03K ﹤0.01% 2220
2024
Q2 		$478 Buy
+15
New +$439 ﹤0.01% 2557

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Smartleaf Asset Management's PTGX Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 48% in Q1 2026, selling an estimated $74.1K and leaving 890 shares worth $88.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1180.

Smartleaf Asset Management first reported a position in PTGX in Q2 2024 and has held it in 8 quarters since. The position peaked at $151K in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Smartleaf Asset Management held 890 shares of Protagonist Therapeutics worth $88.9K as of Q1 2026.
  • Smartleaf Asset Management sold 837 Protagonist Therapeutics shares in Q1 2026, an estimated $74.1K.
  • Protagonist Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #1180 holding.
  • Smartleaf Asset Management first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Smartleaf Asset Management's Protagonist Therapeutics position peaked at $151K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.